Related Experiment Video
Updated: May 10, 2025
05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
20.6K
Thromboprophylaxis in Children: Navigating Uncharted Waters.
1Department of Pediatric Hematology and Oncology, Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands.
Hamostaseologie
|April 27, 2025
Summary
Pediatric thrombosis is rising, necessitating better prevention in hospitalized children. Current strategies lack strong evidence, requiring careful risk assessment for safe management.
Area of Science:
- Pediatric Thrombosis
- Vascular Medicine
- Hematology
Background:
- Pediatric thrombosis incidence is increasing by nearly 10% annually.
- Hospitalized children are particularly vulnerable to venous thromboembolism (VTE).
- Existing preventive strategies require further evidence-based validation.
Purpose of the Study:
- To review current literature on VTE prevention in pediatric patients.
- To clarify thromboprophylaxis strategies for specific pediatric groups.
- To identify evidence gaps in pediatric VTE prevention.
Main Methods:
- Narrative review of existing literature.
- Focused analysis on pediatric surgical and medical conditions.
- Exploration of thromboprophylaxis guidelines.
Main Results:
- Limited evidence exists for best practices in pediatric thromboprophylaxis.
- Current strategies are based on individual risk assessments.
- Specific patient groups (e.g., post-surgery, leukemia) present unique challenges.
Conclusions:
- Effective VTE prevention in pediatric patients remains an area with significant evidence gaps.
- Clinicians must balance thrombotic and bleeding risks in the absence of definitive guidelines.
- Further research is crucial to establish evidence-based thromboprophylaxis protocols for children.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
991
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
991
01:24Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
01:16Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K